Back to Search

Whole-genome Sequencing for Children with Cancer

Cancer Predisposition Testing by Family-based Whole-genome Sequencing (WGS) in Every Child With Newly Diagnosed Cancer

Recruiting Observational Study
Neoplastic Syndromes, Hereditary Cancer Genetic Predisposition to Disease
No Placebo Group Every participant receives an active treatment — no one gets a placebo. No Study Drug Researchers observe your health over time — no experimental treatment is given.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
Up to 21
Sex
Any
Study type
Observational
Participants needed
270 (estimated)
Sponsor
Sydney Children's Hospitals Network · Other
Who this trial is looking for

This trial is looking for children and young adults with a new cancer diagnosis. Participants will help researchers learn more about cancer risk through genetic testing of their family members.

Are You a Good Fit for This Trial?

You may be able to join if

  • I have been diagnosed with cancer.
  • I am 21 years old or younger.
  • I can provide written consent.

Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.

Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial

Assessment of the utility of family-based (trio) whole-genome sequencing for cancer predisposition testing in sequential newly diagnosed paediatric and adolescent cancer patients

Trial Locations

Loading trial locations…

Eligibility Criteria
* New diagnosis of malignancy * Age ≤ 21 years * Written informed consent Psychosocial component: * Participants (≥ 12 years) * Parent/caregiver(s) of participants * Healthcare professionals involved in the care of patients enrolled in the study
Contacts

Clinical Trials Manager

+61 2 9382 3122

SCHN-PREDICT@health.nsw.gov.au

CONTACT

NCT ID: NCT04903782 Source: ClinicalTrials.gov